Exploring Low-Dose Naltrexone as a Potential Treatment for Long COVID
Research from Griffith University suggests that low-dose naltrexone, a drug used for opioid addiction, may be an effective treatment for Long COVID by restoring cellular function and improving symptoms.
Recent research from Griffith University has indicated that low-dose naltrexone (LDN), a medication traditionally used for opioid addiction, may offer new hope in the fight against Long COVID. A study published in Frontiers in Molecular Biosciences demonstrated that LDN successfully restored cellular function in human cells affected by Long COVID.
Long COVID, affecting over 77 million people worldwide, causes persistent symptoms such as fatigue, neurological issues, and immune dysfunction long after the initial infection resolves. The study’s lead researcher, Professor Sonya Marshall-Gradisnik of Griffith’s National Center for Neuroimmunology and Emerging Diseases (NCNED), emphasized the urgency for effective treatments, and highlighted that LDN is a safe, repurposed drug.
The team’s prior investigations revealed that TRPM3 ion channels, which facilitate calcium transport into cells and are vital for cellular signaling, are faulty in Long COVID patients. Ph.D. candidate Etianne Sasso explained that these defective ion channels can be likened to malfunctioning doors in a house, preventing essential calcium entry. This impairment hampers various bodily functions, including immune responses and neurological activity.
The study demonstrated that low-dose naltrexone effectively fixes these dysfunctional 'doors,' enabling proper opening and closing of ion channels. Since these channels influence key processes such as immune response and pain regulation, restoring their function could significantly alleviate Long COVID symptoms. Currently, NCNED is conducting clinical trials to evaluate LDN’s effectiveness in improving symptoms, disability, and quality of life among Long COVID patients.
This promising discovery offers a new avenue for treating a condition that has been challenging to manage and highlights the potential of drug repurposing in medical research.
Source: https://medicalxpress.com/news/2025-05-drug-typically-opioid-addiction-covid.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Pioneering Islet Cell Transplant with Lantidra Achieved at UI Health
UI Health has performed the first FDA-approved islet cell transplant with Lantidra, providing new hope for adults with severe type 1 diabetes by eliminating the need for daily insulin injections.
The Diabetes Paradox: Health Gains Not Translating into Better Workforce Participation
Despite significant health advancements, people with diabetes still face lower employment rates and higher disability claims. Recent research uncovers the persistent 'diabetes paradox' impacting workforce participation and highlights the need for comprehensive strategies to improve economic engagement.
Ethical and Policy Challenges of Lab-Grown Reproductive Cells: New Insights
A new report explores the ethical and policy issues surrounding in vitro gametogenesis, a groundbreaking technology that could revolutionize fertility treatments and reproductive options, including for same-sex couples. The report calls for careful, collaborative discussion before clinical use.